Breaking News
November 12, 2018 - Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)
November 12, 2018 - Scientists reveal new cystic fibrosis treatments work best in inflamed airways
November 12, 2018 - Testing coronary calcium levels can better predict patient’s risk for coronary heart disease
November 12, 2018 - FDA conducts mass seizure of food and medical products held under insanitary conditions
November 12, 2018 - FDA Approves Invokana (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
November 12, 2018 - Hormone helps reverse brain damage caused by obesity
November 12, 2018 - Grants aim to provide better cancer clinical trial access for military veterans
November 12, 2018 - Mitochondrial DNA may have strong influence on cellular metabolism and disease susceptibility
November 12, 2018 - High stakes, entrenched interests and the Trump rollback of environmental regs
November 12, 2018 - Stem cells transplanted for treatment of Parkinson’s disease
November 12, 2018 - Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)
November 12, 2018 - Protein found in patients with severe asthma can help identify who would benefit from targeted drugs
November 12, 2018 - Experts develop a list of competencies in antimicrobial prescribing and stewardship
November 12, 2018 - Allied BioScience receives approved label from EPA for new bacteriostatic surface coating
November 12, 2018 - FDA announces emergency use authorization of Ebola fingerstick test with portable reader
November 12, 2018 - Grieving spouses with sleep problems have increased risk of chronic immune activation
November 12, 2018 - Exercise routines affect mental health in Japanese expatriates
November 12, 2018 - Fish oil and vitamin D pills no guard against cancer or serious heart trouble
November 12, 2018 - Excess Gestational Weight Gain Not Better for Child Bone Health
November 12, 2018 - Immune receptor provides protective immunity against Group A Streptococcus
November 12, 2018 - Scientists develop new method to produce irradiated nanomaterials for medical applications
November 12, 2018 - Blue light exposure decreases blood pressure
November 12, 2018 - Researchers discover two proteins essential for development of skeletal muscle
November 12, 2018 - Yelp reviews help understand strengths, weaknesses of emergency departments and urgent care centers
November 12, 2018 - Adolescent obesity linked with increased risk of pancreatic cancer later in life
November 12, 2018 - AHA: Poor Teeth-Brushing Habits Tied to Higher Heart Risk
November 12, 2018 - Researchers find how natural killer cells regulate protective HIV antibodies
November 12, 2018 - Rutgers receives $4.2 million federal grant to improve mental health services
November 12, 2018 - Sussex scientists develop a piece of hardware to show how brains function
November 12, 2018 - Study shows pivotal role of parents in efforts to change sexual orientation of LGBT teens
November 12, 2018 - Neck scan detects dementia way before symptoms appear
November 12, 2018 - Risk-profiling can benefit HIV prevention
November 12, 2018 - New thrombolytic based on magnetite nanoparticles successfully tested on animals
November 12, 2018 - Smoking rates go down in the US, lowest since 1965
November 12, 2018 - Phase III Trial of Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint
November 12, 2018 - Moderate exercise before conception resulted in lower body weight, increased insulin sensitivity of offspring
November 11, 2018 - Community choirs for older adults reduce loneliness and increase interest in life
November 11, 2018 - Trevena Receives Complete Response Letter for Oliceridine from FDA
November 11, 2018 - More adults and children are using yoga and meditation
November 11, 2018 - Female smokers at greater risk of heart attacks, finds study
November 11, 2018 - Happy Childhood Memories Associated With Better Health
November 11, 2018 - X-linked infantile spinal muscular atrophy – Genetics Home Reference
November 11, 2018 - RNA thought to spread cancer shows ability to suppress breast cancer metastasis
November 11, 2018 - Study finds that thymus plays key role during normal pregnancy
November 11, 2018 - Exploring why some athletes ice their muscles after exercise
November 11, 2018 - Female Genital Mutilation Decreasing in African Nations
November 11, 2018 - Are humans immune to the CRISPR-Cas9 gene editing scissors?
November 11, 2018 - Breastmilk and saliva mixtures regulate oral microbiome of newborn babies
November 11, 2018 - Learning familiar faces through social interactions reduces variability in face recognition
November 11, 2018 - New open source decision support tool could help clinicians chose chemotherapy drugs
November 11, 2018 - New weapons drawn in global TB fight
November 11, 2018 - UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
November 11, 2018 - Surgery restores boy’s ability to walk post-acute flaccid myelitis
November 11, 2018 - Comorbidity negatively impacts quality of life in people with dementia
November 11, 2018 - Neuroscientists receive $16.75 million from BRAIN Initiative to decipher the brain’s visual system
November 11, 2018 - Purdue researchers invent new smart drainage device to help glaucoma patients
November 11, 2018 - New initiative may benefit entrepreneurs working to transform patient care
November 11, 2018 - Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of Zulresso (brexanolone) Injection for Treatment of Postpartum Depression
November 11, 2018 - Exercise could delay progression of type 1 diabetes when first diagnosed
November 11, 2018 - Study of gaze fixation in monkeys reveals role of dopamine neurons in response inhibition
November 11, 2018 - Bilingual therapy is vital to improve language disorders in dual-language children, finds study
November 11, 2018 - More Frequent Surveillance No Benefit After NSCLC Resection
November 11, 2018 - Phenylketonuria (PKU) Screening: MedlinePlus Lab Test Information
November 11, 2018 - Researchers discovered a new mechanism of action in a first-line drug for diabetes
November 11, 2018 - Study explains how dermal fibroblasts age
November 11, 2018 - New multi-allergen test works just as well with dried blood
November 11, 2018 - CWRH/UH researcher receives grant to study role of KLF2 factor in vascular-related disorders
November 11, 2018 - New infrared detector may transform smartphones into pocket-sized portable labs
November 11, 2018 - AHA: Young Golfer Returns to Sport He Loves After Stroke
November 11, 2018 - Yuan-Harel-Lupski syndrome – Genetics Home Reference
November 11, 2018 - Effective diagnosis of persistent facial pain will benefit patients and save money
November 11, 2018 - Loyola tests new catheter ablation system that can reach deeper into heart muscle
November 11, 2018 - Pilates exercise program offers many benefits for people with musculoskeletal conditions
November 11, 2018 - Mutant p53 protein ‘tackles’ DNA guardian to drive tumor development
November 11, 2018 - House Dems in new seats of power will steer health policy, attack drug prices
November 11, 2018 - Maximal longevity in species can be better explained by number of neurons in the brain
November 10, 2018 - Research on designing, delivering, physical activity programs for different audiences
November 10, 2018 - Why heart contractions are weaker in those with hypertrophic cardiomyopathy
November 10, 2018 - AbbVie’s Upadacitinib Shows Significant Improvements in Physical Function, Pain and Quality of Life as a Monotherapy in Patients with Rheumatoid Arthritis in Phase 3 Patient-Reported Outcomes Data
November 10, 2018 - Acute Flaccid Myelitis: MedlinePlus
Study of men with inherited DNA repair mutations opens new therapeutic avenues in prostate cancer

Study of men with inherited DNA repair mutations opens new therapeutic avenues in prostate cancer

image_pdfDownload PDFimage_print

Selected by the American Society of Clinical Oncology (ASCO) to first outing during its Genitourinary Cancers Symposium, Translating Evidence to Multidisciplinary Care, February 8 – 10 (San Francisco, USA), Joaquin Mateo, Principal Investigator of VHIO’s recently created Prostate Cancer Translational Research Group, will today reveal findings from a retrospective and international study showing for the first time that patients with inherited DNA repair mutations benefit from standard therapies in a similar way to other metastatic prostate cancer patients.

Timed to coincide with Joaquin Mateo’s presentation at this week’s ASCO meeting, these results will be published today in the prestigious journal European Urology.

Given that standard therapies traditionally target the hormonal basis of prostate cancer – as opposed to genetic mutation – the team sought to evidence whether patients with metastatic prostate cancer with identified DNA-repair gene mutations, typically found in one out of every ten of these patients, could derive similar benefit from treatment with standard of care therapies. In so doing, they aimed to establish the prognostic and predictive value of these alterations towards a more personalized stratification of patients.

Between 2005 – 2015, the most common cancer for men was prostate cancer with an estimated 1.6 million cases. Recent findings suggest that while it is relatively rare for prostate cancer to spread in the body, metastatic and aggressive prostate cancer is on the rise.

“While prostate tumors are more generally slow-growing than other cancers, the reality in Spain alone is that this disease claims the lives of 6,000 individuals every year. Translational studies aimed at better identifying which patients would most likely benefit from both standard therapies as well as novel anti-cancer approaches are critical if we are to ultimately improve outcomes for patients with metastatic disease”, observes Joaquin, first author of the study.

Until quite recently, prostate cancer was considered to be exclusively dependent on male androgens fuelling prostate cancer cell growth, and the majority of anti-cancer therapies have thus focused on tackling this tumor type from this angle. Current research is rapidly transforming the way in which prostate cancer is both considered and managed, paving the way for more effective and tailored treatment approaches.

Previous findings published in Cell in 2015 showed that between 20-25% of patients with metastatic prostate cancer had DNA-repair related mutations as well as BRCA mutations, or similar.

In 2016, Mateo and colleagues evidenced that DNA-repair gene mutations are found inherited in one out of every ten men with metastatic prostate cancer. This discovery, published in The New England Journal of Medicine, has since placed these mutations firmly under the lens in efforts aimed at benefiting an increasing number of these patients.

Additional research has therefore centered on showing whether individuals with these identified mutations could better respond to other treatments. Clinical findings also reported by Joaquin and co-collaborators from the Institute of Cancer Research – Royal Marsden NHS Foundation Trust (London, UK), revealed that some of these patients responded to PARP inhibitors, which are already approved in the case of metastatic breast cancer and ovarian cancer in carriers of mutations in BRCA.

This discovery has since led to several currently ongoing international clinical trials in prostate cancer. The next step was to analyze treatment response in these patients to establish whether this inherited genetic variation affects the efficacy of therapy.

In this latest study, results were analyzed for a total of 390 metastatic prostate cancer patients with DNA-repair gene mutations to assess response to standard treatments. Findings indicate that patients with BRCA mutations respond to these therapies in a similar way to other patients with metastatic prostate cancer patients without these mutations.

Overall survival and disease-free progression were therefore comparable and no significant differences in response rate to first-line treatment were observed. In addition, a trend toward greater overall survival was noted in those patients with mutations who had participated in studies with PARP inhibitors or platinum-based therapy.

“Since this cohort of patients is the first with long-term data available on the response to post-therapy with PARP inhibitors and platinum-based agents, our research also marks an important first. We are seeing that patients with these mutations not only benefit from standard treatments, but may also have additional therapeutic options available”, explains Joaquin.

“While our data are still preliminary, I believe that we have every reason to be optimistic about these initial results. Importantly, with several trials with PARP Inhibitors for prostate cancer currently underway at VHIO, new clinical data to emerge from these studies will hopefully further support the use of these inhibitors in the treatment of our patients”, he concludes.

Joining forces with VHIO’s Genitourinary, CNS Tumors, Sarcoma & Cancer of Unknown Primary Site Group Cancer led by Joan Carles, also located within the Vall d´Hebron Barcelona Hospital Campus, Joaquin’s Prostate Cancer Translational Research Group will pioneer research aimed at translating prostate cancer genotypes into phenotypes and a clinically-relevant classification of the disease. These teams will also seek to build a precision medicine core for prostate cancer patients.

His group’s expertise, combined with that of Joan Carles, will accelerate the translation of the use of PARP inhibitors as a more effective therapy for metastatic prostate cancer patients to the clinic. Currently open clinical studies performed at VHIO, matched to the molecular alterations and specificities detected in individual patients, are possible thanks to its renowned prescreening program, pioneered by VHIO’s Cancer Genomics and Molecular Oncology Groups, led by Ana Vivancos and Paolo Nuciforo, respectively.​

Source:

Genetic gene mutations: opening new therapeutic avenues in metastatic prostate cancer

Tagged with:

About author

Related Articles